📰 Risk Evaluation News
Page 14 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
November 14, 2023
(BPT) - People with narcolepsy may be unaware that their chronic condition may increase their odds of having a stroke*, heart disease†, hypertension†, diabetes†, and other …
November 9, 2023
Pharmacists should consult state boards of pharmacy and local, state, or national associations to understand how regulations apply to them
November 6, 2023
The U.S. Environmental Protection Agency (EPA) proposed on October 31, 2023, to ban all uses of trichloroethylene (TCE) after determining that it presents an unreasonable risk of...
November 2, 2023
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
November 1, 2023
Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® and $23.9 million for EMPAVELI® SYFOVRE showed continued strong demand with growth...
November 1, 2023
Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny.
November 1, 2023
The U.S. Environmental Protection Agency (EPA) announced on October 19, 2023, a proposed rule that would amend the procedural framework rule for conducting risk evaluations under the...
October 31, 2023
The U.S. Environmental Protection Agency (EPA) published proposed revisions of its procedural rule on risk evaluations under TSCA on October…
October 27, 2023
The Q3 earnings season is in full swing, and we’ve already seen the first wave of big tech results. Investors were not thrilled; Google parent Alphabet reported a slowdown in cloud revenues, and the stock market fell sharply on sentiment that Q3 earnings may not be as pretty as predicted. But the outlook is less cloudy for the coming year. In a recent note on current and coming conditions, investment bank Morgan Stanley notes that growth is expected to jump heading into next year: “...
October 25, 2023
Doctors hope FDA approval of a pill for postpartum depression called Zuranolone (under the brand name Zurzuvae) could raise awareness and increase treatment options for this debilitating condition.